<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<TITLE>$titleTag</TITLE>
<STYLE type="text/css">
   subtoolbar {border-top-width: 0px; border-top-style: none;}


   
 </STYLE>	
</head>
<body>
	
	<table width="940" height="496" border="0" align="center" cellpadding="0" cellspacing="0">
		<tr>
			<td height="489" align="right" valign="top"><SPAN><BR><INPUT type="BUTTON" name="BUTTON" value="< BACK" onclick="javascript: history.go(-1)" /></SPAN><BR>
			<table width="100%">
				<tr valign="top" align="left" style="color:#0066FF">
					<th width="33%">j50000007</th>
					<th width="33%">i20790082</th>
					<th width="33%"><A HREF='http://phoenix.jstor.org/Phoenix/toc/secure/issue.html?workType=mod&journalId=10.2307/j50000007&issueId=10.2307_i20790082' target='_blank'>PHX Link</A></th>
				</tr>
			</table>
			<P align='left' style='color:#993300'><B><u>10.2307/20790096</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Identification of factors associated with the presence of human immunodeficiency virus (HIV) in female genital secretions is critical for intervention strategies targeting transmission and eliminating replication of genital virus. We sought to monitor the prevalence of genital HIV shedding in antiretroviral therapy—adherent women over time and to assess changes in the genital microenvironment.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Identification of factors associated with the presence of human immunodeficiency virus (HIV) in female genital secretions is critical for intervention strategies targeting transmission and eliminating replication of genital virus. We sought to monitor the prevalence of genital HIV shedding in antiretroviral therapy—adherent women over time and to assess changes in the genital microenvironment.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Levels of cell-free HIV (HIV RNA) and HIV-infected cells (HIV DNA) were monitored in peripheral blood samples and cervical and vaginal fluid samples at monthly intervals in 11 women for 1 year. Genital tract infections and fluctuations in cervical and vaginal white blood cell counts were also evaluated at each study visit.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Plasma HIV was undetectable at the majority of study visits; when detected, it was only at low levels. Throughout the study, genital HIV RNA and DNA were detected in each person. Combined genital HIV (RNA and DNA) was detected at 49.2% of study visits and was associated with an elevated concentration of cervical white blood cell infiltrate (odds ratio, 2.52 [95% confidence interval, 1.01—6.22]; P = .04). Infiltrate was not associated with a clinical disorder or patient-reported symptoms.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. Despite antiretroviral therapy adherence and clinically suppressed plasma viremia, HIV was intermittently detected in genital secretions and was associated with subclinical inflammation and cells trafficking to the cervical mucosa.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790097</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. In 8 HIV-1-positive adults who were receiving ART and had CD4? T cell counts of >200 cells/?L and plasma viral loads of <40 copies/mL, levels of HIV and T cell activation were measured in blood samples and endoscopic biopsy specimens from the duodenum, ileum, ascending colon, and rectum.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. HIV DNA and RNA levels per CD4? T cell were higher in all 4 gut sites compared with those in the blood. HIV DNA levels increased from the duodenum to the rectum, whereas the median HIV RNA level peaked in the ileum. HIV DNA levels correlated positively with T cell activation markers in peripheral blood mononuclear cells (PBMCs) but negatively with T cell activation markers in the gut. Multiply spliced RNA was infrequently detected in gut, and ratios of unspliced RNA to DNA were lower in the colon and rectum than in PBMCs, which reflects paradoxically low HIV transcription, given the higher level of T cell activation in the gut.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. HIV DNA and RNA are both concentrated in the gut, but the inverse relationship between HIV DNA levels and T cell activation in the gut and the paradoxically low levels of HIV expression in the large bowel suggest that different processes drive HIV persistence in the blood and gut.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>5</TD><TD width='5%' bordercolor='blue'>Trial registration. ClinicalTrials.gov identifier: NCT00884793 (PLUS1).</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790086</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. There are questions regarding the prevalence of xenotropic murine leukemia virus—related virus (XMRV) in patients with prostate cancer and its association with the RNASEL R462Q polymorphism. We therefore investigated whether XMRV infection could be found in patients with prostate cancer from the southern United States, and we sought to verify the association with the R462Q.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. There are questions regarding the prevalence of xenotropic murine leukemia virus—related virus (XMRV) in patients with prostate cancer and its association with the RNASEL R462Q polymorphism. We therefore investigated whether XMRV infection could be found in patients with prostate cancer from the southern United States, and we sought to verify the association with the R462Q.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Prostate tissue specimens of 144 patients with prostate cancer from the southern United States were genotyped for R462Q by real time polymerase chain reaction allelic discrimination and were screened for XMRV proviral DNA by nested polymerase chain reaction specific for the env gene.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. The R462Q polymorphism was found at an allelic frequency of 0.33. XMRV was detected in 32 (22%) of the 144 patients. Patients were significantly more likely to test positive for XMRV in both tumor and normal tissue rather than either alone (? = 0.64). A positive result for XMRV was not significantly correlated with the R462Q polymorphism (P = .82) or clinical pathological parameters of prostate cancer, including Gleason score (P = .29).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. XMRV is detectable in normal and tumor prostate tissue from patients with prostate cancer, independent of R462Q. The presence of XMRV in normal tissue suggests that infection may precede cancer onset.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790091</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Hepatitis B vaccine provides a model for improving uptake and completion of multidose vaccinations in the drug-using community.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Hepatitis B vaccine provides a model for improving uptake and completion of multidose vaccinations in the drug-using community.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. The Drugs, AIDS, STDs, and Hepatitis (DASH) project conducted a randomized controlled trial among not-in-treatment current drug users in 2 urban neighborhoods. Neighborhoods were cluster-randomized to receive a standard behavioral intervention (which provided information on human immunodeficiency virus [HIV] or an enhanced behavioral intervention (designed to increase acceptance of or adherence to the hepatitis B vaccination protocol). Participants within clusters were randomized to a standard vaccination schedule (vaccines at 0, 1, and 6 months) or an accelerated vaccination schedule (vaccines at 0, 1, and 2 months). The outcomes were completion of the 3-dose vaccine and seroprotection against hepatitis B virus (HBV).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Of participants with negative screening results for HIV and HBV, 77% accepted hepatitis B vaccination, and 75% of vaccines received all 3 doses. Injection drug users (IDUs) on the accelerated schedule were significantly more likely to receive 3 doses (76%) than those on the standard schedule (66%; P = .04), although for drug users as a whole the corresponding adherence rates were 77% and 73%, respectively. No difference in adherence was observed between the behavioral intervention groups. Predictors of adherence were older age, African American race, stable housing, and alcohol use. Cumulative HBV seroprotection (? 10 mIU/mL) was gained within 12 months by 65% of those completing the schedule. Seroprotection at 6 months was greater for those on the accelerated schedule.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. The accelerated vaccination schedule improves hepatitis B vaccination adherence among IDUs.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790092</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Introduction. RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log?? IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Introduction. RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log?? IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Results. From 32 patients treated with RG7128 monotherapy for 2 weeks, marginal viral load rebound was observed in 3 HCV genotype 1—infected patients, whereas partial response was observed in 2 genotype 1—infected patients. From 85 patients receiving RG7128 in combination with SOC, 1 HCV genotype 1—infected patient experienced a viral rebound, and 2 genotype 3—infected patients experienced a transient rebound. Five genotype 1—infected patients had an HCV load of >1000 IU/mL at the end of 4-week treatment. No viral resistance was observed, per NS5B sequencing and phenotypic studies. PSI-6130 resistance substitution S282T needs to be present at levels of ?90% within a patient's quasispecies to confer low-level resistance. No evidence of S282T was found by population or clonal sequence analyses.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Conclusions. The requirement for a predominant S282T mutant quasispecies, its low replication capacity, and the low-level resistance it confers probably contribute to the lack of RG7128 resistance observed in HCV-infected patients.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790093</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Measles affected entire birth cohorts in the prevaccine era but was declared eliminated in the United States in 2000 because of a successful measles vaccination program.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Measles affected entire birth cohorts in the prevaccine era but was declared eliminated in the United States in 2000 because of a successful measles vaccination program.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. We reviewed US surveillance data on confirmed measles cases reported to the Centers for Disease Control and Prevention and data on national measles-mumps-rubella (MMR) vaccination coverage during postelimination years 2001—2008.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. During 2001—2008, a total of 557 confirmed cases of measles (annual median no. of cases, 56) and 38 outbreaks (annual median no. of outbreaks, 4) were reported in the United States; 232 (42%) of the cases were imported from 44 countries, including European countries. Among case-patients who were US residents, the highest incidences of measles were among infants 6—11 months of age and children 12—15 months of age (3.5 and 2.6 cases/1 million person-years, respectively). From 2001 through 2008, national 1-dose MMR vaccine coverage among children 19—35 months of age ranged from 91% to 93%. From 2001 through 2008, a total of 285 US-resident case-patients (65%) were considered to have preventable measles (ie, the patients were eligible for vaccination but unvaccinated). During 2004—2008, a total of 68% of vaccine-eligible US-resident case-patients claimed exemptions for personal beliefs.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. The United States maintained measles elimination from 2001 through 2008 because of sustained high vaccination coverage. Challenges to maintaining elimination include large outbreaks of measles in highly traveled developed countries, frequent international travel, and clusters of US residents who remain unvaccinated because of personal belief exemptions.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790094</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Few randomized trials comparing antiretroviral therapy (ART) regimens have been conducted in resource-limited settings.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Few randomized trials comparing antiretroviral therapy (ART) regimens have been conducted in resource-limited settings.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. In the Republic of South Africa, antiretroviral-naive human immunodeficiency virus (HIV)—infected individuals >14 years old with a CD4 cell count <200 cells/?L or a prior AIDS diagnosis were randomized to receive efavirenz (EFV) or lopinavir/ritonavir (LPV/r) with either zidovudine (ZDV) plus didanosine (ddI) or stavudine (d4T) plus lamivudine (3TC) in an open-label, 2-by-2 factorial study and followed up for the primary outcome of AIDS or death and prespecified secondary outcomes, including CD4 cell count and viral load changes, treatment discontinuation, and grade 4 events.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. In total, 1771 persons were randomized and followed up for a median of 24.7 months. AIDS or death occurred in (1) 163 participants assigned EFV and 157 assigned LPV/r (hazard ratio [HR], 1.04 [95% confidence interval {CI}, 0.84—1.30]) and in (2) 170 participants assigned ZDV+ddI and 150 assigned d4T+3TC (HR, 1.15 [95% CI, 0.93—1.44]). HIV RNA levels were lower (P < .001) and CD4 cell counts were greater (P < .01) over follow-up for d4T+3TC versus ZDV+ddI. Rates of potentially life-threatening adverse events and overall treatment discontinuation were similar for d4T+3TC and ZDV+ddI; however, more participants discontinued d4T because of toxicity (12.6%) than other treatments (<5%).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. EFV and LPV/r are effective components of first-line ART. The poorer viral and immune responses with ZDV+ddI and the greater toxicity-associated discontinuation rate with d4T+3TC suggest that these treatments be used cautiously as initial therapy.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>5</TD><TD width='5%' bordercolor='blue'>Trial registration. ClinicalTrials.gov identifier: NCT00342355.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790101</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Antibiotic combination therapy might be more efficient than single antibiotics to combat Pseudomonas aeruginosa biofilms in the airways of patients with cystic fibrosis. We tested the ability of colistin sulphate—tbramycin combinations and single antibiotics to kill P. aeruginosa biofilms.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Antibiotic combination therapy might be more efficient than single antibiotics to combat Pseudomonas aeruginosa biofilms in the airways of patients with cystic fibrosis. We tested the ability of colistin sulphate—tbramycin combinations and single antibiotics to kill P. aeruginosa biofilms.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. P. aeruginosa biofilms were generated in vitro and in rat lungs. In a pilot study, 5 patients with cystic fibrosis inhaled colistin and then tobramycin for 4 weeks. The changes in P. aeruginosa counts and lung function were assessed before and after therapy.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Antibiotic combination therapy significantly reduced the number of P. aeruginosa cells in P. aeruginosa biofilm models in vitro. When rats were challenged with 1 × 10? cfu of P. aeruginosa, which was embedded in alginate beads, mortality rates, lung pathologic findings, and bacterial colony-forming unit counts were significantly lower after 7 days in animals receiving antibiotic combination than in animals receiving single antibiotics. In patients with cystic fibrosis, inhaled colistin-tobramycin was well tolerated and resulted in a mean decrease of 2.52 ± 2.5 log?? cfu of P. aeruginosa per milliliter of sputum (P = .027). Measurements of forced expiratory volume in 1 s, obtained both before and after the study, did not differ significantly.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. Colistin-tobramycin combinations are more efficient than respective single antibiotics for killing P. aeruginosa in biofilms in vitro, and they significantly reduced P. aeruginosa cell counts in a rat lung infection model and in patients with cystic fibrosis.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790099</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The prevalence of and risk factors for abnormal anal cytology among men and women with human immunodeficiency virus (HIV) infection have not been extensively investigated.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. The prevalence of and risk factors for abnormal anal cytology among men and women with human immunodeficiency virus (HIV) infection have not been extensively investigated.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN study) is a prospective cohort study of HIV-infected patients in 4 US cities. Baseline questionnaires were administered and anal samples for cytology and human papillomavirus (HPV) detection and genotyping were collected.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Among 471 men and 150 women (median age, 41 years), 78%
of participants were receiving combination antiretroviral therapy, 41% had a CD4? cell count of ?500 cells/?L, and 71% had an HIV RNA viral load of <400 copies/mL. The anal cytology results were as follows: 336 participants (54%) had negative results, 96 participants (15%) had atypical squamous cells, 149 participants (24%) had low-grade squamous intraepithelial lesions, and 40 participants (6%) had high-grade squamous intraepithelial lesions. In a multivariate analysis, abnormal anal cytology was associated with number of high-risk and low-risk HPV types (adjusted odds ratio [AOR] for both, 1.28; P < .001), nadir CD4? cell count of <50 cells/?L (AOR, 2.38; P = .001), baseline CD4? cell count of <500 cells/?L (AOR, 1.75; P = .004), and ever having receptive anal intercourse (AOR, 2.51; P < .001).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusion. HIV-infected persons with multiple anal HPV types or a nadir CD4? cell count of <50 cells/?L have an increased risk for abnormal anal cytology.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790104</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Plasmodium falciparum—infected erythrocytes sequester in the placenta and elicit an inflammatory response that is harmful to both fetus and mother. Histologic measurements during placental malaria might provide surrogate end points for interventional trials, but existing histologic schemes capture limited complexity and are not consistently used among study sites.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Plasmodium falciparum—infected erythrocytes sequester in the placenta and elicit an inflammatory response that is harmful to both fetus and mother. Histologic measurements during placental malaria might provide surrogate end points for interventional trials, but existing histologic schemes capture limited complexity and are not consistently used among study sites.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Using frozen-section histologic evaluation in Tanzania (high-transmission area), we established a novel grading scheme to separately quantify inflammation and pigment deposition during placental malaria (n = 102). To generalize this method, formalin-fixed, paraffin-embedded placental samples from Karen women in Thailand (low-transmission area) were selected from among women with documented antenatal parasitemia who were near term (n = 18).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. In the Tanzanian cohort, the inflammation and pigment-deposition scores were independently associated with birth weight, and the inflammation score was associated with chemokine levels. In the smaller cohort from Thailand, both inflammation and pigment scores were associated with birth weight, and the pigment score had an inverse trend with the number of antenatal clinic visits.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. This semiquantitative pathological grading scheme is simple to implement and captures information that is associated with outcomes in Asia and Africa; therefore, it should facilitate the comparison and standardization of results among clinical trials across areas of differing endemicity.</TD></TR></table><P align='left' style='color:#993300'><B><u>10.2307/20790103</u></B></P><BR><P align='left' style='color:#CC66FF'><B><u>Current Issuemap</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Recombinant human activated protein C (APC) improves survival of patients with severe sepsis; this beneficial effect is especially apparent in patients with pneumococcal pneumonia. The aim of this study was to determine the effect of APC treatment initiated after induction of pneumococcal pneumonia on pulmonary coagulation, inflammation, and survival, with or without concurrent antibiotic therapy.</TD></TR></table><P align='left' style='color:#FF9900'><B><u>Most Eligible Issuemap Info</u></B></P><BR><table width='100%'><TR valign='top'><TD width='5%' bordercolor='blue'>1</TD><TD width='5%' bordercolor='blue'>Background. Recombinant human activated protein C (APC) improves survival of patients with severe sepsis; this beneficial effect is especially apparent in patients with pneumococcal pneumonia. The aim of this study was to determine the effect of APC treatment initiated after induction of pneumococcal pneumonia on pulmonary coagulation, inflammation, and survival, with or without concurrent antibiotic therapy.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>2</TD><TD width='5%' bordercolor='blue'>Methods. Mice were infected intranasally with viable Streptococcus pneumoniae and were treated intraperitoneally after 24 h of infection with vehicle, recombinant mouse (rm) APC (125 ?g), ceftriaxone (500 ?g), or rm-APC plus ceftriaxone. Treatment with rm-APC or vehicle was repeated every 8 h for a maximum of 96 h. Animals were either killed 48 h after infection or were monitored in a survival study (with an extra dose of ceftriaxone given after 72 h).</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>3</TD><TD width='5%' bordercolor='blue'>Results. Rm-APC treatment inhibited pulmonary activation of coagulation, as reflected by lower levels of thrombin-antithrombin complexes and D-dimer. Rm-APC did not affect the pulmonary levels of 55 inflammatory mediators in the context of antibiotic therapy. Rm-APC added to ceftriaxone markedly improved survival, compared with ceftriaxone treatment alone.</TD></TR><TR valign='top'><TD width='5%' bordercolor='blue'>4</TD><TD width='5%' bordercolor='blue'>Conclusions. Rm-APC inhibits pulmonary activation of coagulation and, when added to antibiotic therapy, improves survival in murine pneumococcal pneumonia.</TD></TR></table>
				
		</td>
		</tr>
	</table>		
</body>
</html>
